ClinicalTrials.gg
Drug

Tepotinib clinical trials

Also written MSC2156119J, Tepmetko and EMD 1214063.

studies test it
24
open now
5
in phase 3
1
first study started
2009

How each study uses tepotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tepotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
3 Feb 2021 · TEPMETKO · NDA 214096 (FDA, Drugs@FDA)
European Union
16 Feb 2022 · Tepmetko · EMEA/H/C/005524 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tepotinib
20

Brand

Tepmetko
3

Development codes

MSC2156119J
5
EMD 1214063
2

Studies by the year they started

24 studies that test it; most in 2021 (3)

Studies that test tepotinib, by start year
YearStudies
20091
20132
20142
20162
20182
20192
20202
20213
20223
20232
20241
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
16
Phase 2
13
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 10

Merck KGaA, Darmstadt, Germany (5) · EMD Serono Research & Development Institute, Inc. (4) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (3) · M.D. Anderson Cancer Center (2) · Institute of Cancer Research, United Kingdom (1) · Fondazione per la Medicina Personalizzata (1) · EMD Serono (1) · Helsinki University Central Hospital (1)

Often tested with

Tested in the same studies.

Pembrolizumab (2) · Alectinib (2) · Cobimetinib (2) · HhAntag691 (2) · Trastuzumab (2) · Pertuzumab (2) · Entrectinib (2) · Atezolizumab (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test tepotinib.

Studies

Open first, then newest update. How each study uses tepotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 24

See all 24 studies that test tepotinib →

Given beside what is tested · 4 — tepotinib is usual care or a partner of the new treatment

Codes

What other systems call tepotinib · ClinicalTrials.gg INT001334

  • MeSH (NLM) C000707607tepotinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 1IJV77EI07TEPOTINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2477103One source FDA
  • Wikidata Q27088961tepotinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C88314TepotinibOne source FDA
  • DrugBank DB15133One source Wikidata

Also registered as tepotinib hydrochloride (UNII VY5YX2TQ1F · RxNorm 2477104).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.